FDA Approved Biologics and Pending Applications
Inter Partes Review Proceedings
DUPIXENTIPR2017-01129IPR2017-01879IPR2017-01884EYLEAIPR2020-01317IPR2020-01318IPR2020-01320IPR2021-00402IPR2021-00816IPR2021-00880IPR2021-00881IPR2022-00257IPR2022-00258IPR2022-00298IPR2022-00301IPR2022-01225IPR2022-01226IPR2022-01524IPR2023-00099IPR2023-00442IPR2023-00462IPR2023-00532IPR2023-00533IPR2023-00566IPR2023-00620IPR2023-00739IPR2023-00884IPR2023-01312IPR2024-00201PGR2021-00035PGR2021-00117GENENTECH CABILLYIPR2015-01624EYLEA / CT-P42IPR2022-00257IPR2022-00258IPR2023-00462IPR2023-00532IPR2023-00533IPR2023-00620PGR2021-00117EYLEA / LUCENTISIPR2020-01317IPR2020-01318IPR2020-01320IPR2021-00816EYLEA / M710IPR2021-00880IPR2021-00881IPR2022-01225IPR2022-01226IPR2023-00099EYLEA / SB15IPR2023-00442IPR2023-00566IPR2023-00739IPR2023-00884IPR2023-01312
U.S. Patent Litigations
DUPIXENT1:17-cv-10465 (D. Mass.)2:17-cv-02613 (C.D. Cal.)EYLEA1:18-cv-02434 (S.D.N.Y.)1:20-cv-00690 (N.D.N.Y.)1:22-cv-00061 (N.D.W.Va.)1:23-cv-00089 (N.D.W.Va.)1:23-cv-00094 (N.D.W.Va.)ZALTRAP1:18-cv-02434 (S.D.N.Y.)7:11-cv-09463 (S.D.N.Y.)EYLEA / CT-P421:23-cv-00089 (N.D.W.Va.)EYLEA / LUCENTIS / ZALTRAP1:18-cv-02434 (S.D.N.Y.)EYLEA / M7101:22-cv-00061 (N.D.W.Va.)EYLEA / SB151:23-cv-00094 (N.D.W.Va.)PRALUENT / GENENTECH CABILLY2:15-cv-05685 (C.D. Cal.)PRALUENT / REPATHA1:14-cv-01317 (D. Del.)1:14-cv-01349 (D. Del.)1:14-cv-01393 (D. Del.)1:14-cv-01414 (D. Del.)